EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU ( CUARTA LINEA MÚLTIPLE MYELOMA ) .

AJMC : SE AVECINA UNA NUEVA ERA EN LOS TRATAMIENTOS PARA SMALL CELL LUNG CANCER Y DESTACAN LÓGICAMENTE AL TARLATAMAB DE AMGEN TANTO PARA PRIMERA LÍNEA , PARA PRIMERA LÍNEA DE MANTENIMIENTO EN COMBINACIÓN CON DURVALUMAB DE ASTRAZÉNECA , PARA SEGUNDA LINEA ... ¡¡¡ TODAS LAS LINEAS !!! .

AJMC , 22 JULY 2025 : IS A NEW ERA OF SCLC TREATMENTS ON THE HORIZON .

One of the most significant developments has been the targeting of delta-like ligand 3 (DLL3), a protein highly expressed in both SCLC and LCNEC .

TARLATAMAB ( IMDELLTRA; AMGEN ), a DLL3-targeting bispecific T-cell engager (BiTE), received the green light from the FDA for use in previously treated patients with extensive-stage SCLC in 2024 .

The Accelerated approval was based on results from the phase 2 DeLLphi-301 study, showing an overall response rate (ORR) of 40% in patients who had received 2 or more prior lines of treatments .

The BiTE is currently being assessed in several PHASE III TRIALS, including DeLLphi-304, DeLLphi-305, and DeLLphi-306 . 

THESE TRIALS AIM TO ASSESS TARLATAMAB BOTH AS A MONOTHERAPY AND IN COMBINATION WITH THE PD-L1 INHIBITOR DURVALUMAB ( IMFINZI; ASTRAZÉNECA ), IN PRVIOUSLY TREATED AND MAINTENANCE SETTINGS . ...

Kicking Off @OncLive Bridging The Gaps in Lung Cancer With Small Cell Lung Cancer -@DrRaviSalgia Reviews Emerging Biomarkers Driving Potential 2L+ Therapeutic Options For Patients With ES-SCLC #BTGLung2025 .